Authors: Will, BP Berthelot, JM Le Petit, C Tomiak, EM Verma, S Evans, WK

Citation: Bp. Will et al., Estimates of the lifetime costs of breast cancer treatment in Canada, EUR J CANC, 36(6), 2000, pp. 724-735

Authors: Yau, JC Gertler, SZ Hanson, J Verma, S Grimard, LJ Malik, ST Aref, IM Cross, PW Tomiak, EM Stewart, DJ St Cyr, DA Huan, SD

Citation: Jc. Yau et al., A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma, AM J CL ONC, 23(3), 2000, pp. 292-296

Authors: Stewart, DJ Goel, R Gertler, SZ Huan, S Tomiak, EM Yau, J Cripps, C Evans, WK

Citation: Dj. Stewart et al., Concurrent use of multiple low dose chemotherapy agents with differing mechanisms of action as a strategy vs passive resistance: A pilot study, INT J ONCOL, 15(4), 1999, pp. 693-699

Authors: Nabholtz, JM Senn, HJ Bezwoda, WR Melnychuk, D Deschenes, L Douma, J Vandenberg, TA Rapoport, B Rosso, R Trillet-Lenoir, V Drbal, J Molino, A Nortier, JWR Richel, DJ Nagykalnai, T Siedlecki, P Wilking, N Genot, JY Hupperets, PSGJ Pannuti, F Skarlos, D Tomiak, EM Murawsky, M Alakl, M Riva, A Aapro, M

Citation: Jm. Nabholtz et al., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy, J CL ONCOL, 17(5), 1999, pp. 1413-1424

Authors: Will, BP Le Petit, C Berthelot, JM Tomiak, EM Verma, S Evans, WK

Citation: Bp. Will et al., Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs, BR J CANC, 79(9-10), 1999, pp. 1428-1436